What is AZN's current stock price?

As of now, AZN is trading at $93.24, with a daily change of +1.88%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN

Astrazeneca

$93.24

+$1.72 | +1.88%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$93.41

MKT CAP

$288.42B

52W Low

$61.24

VOL

$4.66M

P/E Ratio

30.98

AVG VOL

$4.73M

RSI

75.86

TREND

Uptrend

Latest Comments

$AZN big $2b maryland investment lifts sentiment; trend looks steady with room for continuation

November 22, 2025 01:34 AM

AZN Stock IQ

Login to see Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AZN Target Price

Login to display

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Trading below its fair value

AZN Rewards

Outperform the market

Chart

$82.61 (+12.87%)

$79.9 (+16.70%)

$69.45 (+34.25%)

$68.2 (+36.72%)

1year

6month

3month

1month

AZN Risk Level

AZN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AZN Analysts Opinion

AZN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Performance Sentiment

Sentiments overview associated with AZN events and the stock performance.

100%

0%

Positive

Negative

39 out of 39
events present

0 out of 39
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$91.00

Resistance
Price

$73.53

Current Price Range

$91.00

Show methods +

Linked to AZN

IQ

Close Price

Change

NVS

4.27

130.28

+2.95%

PFE

3.94

25.72

+1.98%

MRK

4.03

105.66

+5.23%

SNY

4.02

50.28

+2.30%

TEVA

4.23

24.99

+0.89%

AZN Latest Analysis +

AstraZenecas Imfinzi granted approval for gastric cancers.

Today

$93.24 | +1.88%

Activity

Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies | DelveInsight. Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies |. DelveInsightChronic heart failure (CHF) is a progressive condition where the heart is unable to pump blood effectively leading to significant morbidity and healthcare burden. The growing elderly population inherently at higher risk for CHF is a major driver

Today

$93.24 | +1.88%

Activity

AstraZeneca stock price target raised to $108.50 from $91.70 at BofA.

Today

$93.24 | +1.88%

Potential

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows. Hong Kong-based ) initially established in March 2025.Harbour BioMed is a biopharmaceutical company focused on the discoveryand developmentof antibody therapeutics in .The collaboration to discover and develop next-generation biotherapeutics including antibody-drug conjugates and T cell engagers.Under the terms of the agreement AstraZeneca will continue to nominate discovery programs to Harbour BioMed each ye

Mon Nov 24, 2025

$91.52 | +0.57%

Activity

AstraZeneca expands United States production footprint with $2B investment in Maryland.

Fri Nov 21, 2025

$91.00 | +2.62%

Activity

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug Koselugo. AstraZeneca secures FDA approval to expand Koselugos use to treat adult NF1 patients with inoperable PN.

Fri Nov 21, 2025

$91.00 | +2.62%

Activity

FDA Approval Delivers Momentum For AstraZenecas Rare Disease Portfolio. On Thursday the United States Food and Drug Administration (FDA) approved )Koselugo (selumetinib) for adult patients with neurofibromatosis type 1 (NF1) who have symptomatic inoperable .NF1 is a rare progressive genetic condition caused by a spontaneous or inherited mutation in the NF1 gene.It is associated with a variety of symptoms including soft lumps on and under the skin (cutaneous neurofibromas) and in up to 50% of pat

Thu Nov 20, 2025

$88.78 | -0.35%

Activity

AstraZenecas Alexion gets FDA approval for Koselugo.

Thu Nov 20, 2025

$88.78 | -0.35%

Activity

AstraZeneca: Alexions Koselugo Gets FDA Approval For Adults With Neurofibromatosis Type 1 . (RTTNews) - British drug major AstraZeneca Plc. (AZN.L AZN) announced Thursday that the US Food and Drug Administration has approved Alexion AstraZeneca Rare Diseases Koselugo (selumetinib) for the treatment of adult patients with neurofibromatosis type 1 or NF1 who have sympt

Thu Nov 20, 2025

$88.78 | -0.35%

Activity

AstraZeneca Pharma India shares surge over 3% on new Hyperkalaemia drug deal with Sun Pharma . On Tuesday shares of AstraZeneca Pharma India surged following the announcement of an exciting alliance with Sun Pharmaceutical Industries. Together they are set to enhance the availability of Sodium Zirconium Cyclosilicate which combats hyperkalemia. AstraZeneca will introduce this treatment to the market under the name Lokelma while Sun Pharma will distribute it as Gimliand.

Tue Nov 18, 2025

$89.55 | +0.17%

Activity

Momentum

FAQ About AZN Stock Insights

What is AZN current stock price?

What are AZN stock strengths?

What is AZN Risk Level?

What is AZN market cap and volume?

What is AZN current Stock IQ?

Should I buy AZN stock right now?

Is AZN a Strong Buy right now?

What does a 'Strong Buy' rating mean for AZN?

What does a 'Strong Sell' rating mean for AZN?

What factors influence AZN's Stock IQ?

Explore our AZN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored AZN Stock Strategies
Effective Risk Management

FIND US ON

Receive our AZN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

AZN

Astrazeneca

Current Price

$93.24

+$1.72 | +1.88%

52W High

$93.41

MKT CAP

$288.42B

52W Low

$61.24

VOL

$4.66M

P/E Ratio

30.98

AVG VOL

$4.73M

RSI

75.86

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Trading below its fair value

AZN Rewards

Outperform the market

Linked to AZN

Symbol

IQ

Close

Change

NVS

4.27

130.28

+2.95%

PFE

3.94

25.72

+1.98%

MRK

4.03

105.66

+5.23%

SNY

4.02

50.28

+2.30%

TEVA

4.23

24.99

+0.89%

Latest Comments

$AZN big $2b maryland investment lifts sentiment; trend looks steady with room for continuation

November 22, 2025 01:34 AM

AZN Stock IQ

Login to unlock Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$82.61 (+12.87%)

$79.9 (+16.70%)

$69.45 (+34.25%)

$68.2 (+36.72%)

1year

6month

3month

1month

AZN Analysts Opinion

AZN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Risk Level

AZN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AZN Performance Sentiment

Sentiments overview associated with AZN events and the stock performance.

100%

0%

Positive

Negative

39 out of 39
events present

0 out of 39
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$91.00

Resistance
Price

$73.53

Current Price Range

$91.00

Show methods +

AZN Latest Analysis

AstraZenecas Imfinzi granted approval for gastric cancers.

Today

$93.24 | +1.88%

Activity

Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies | DelveInsight. Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies |. DelveInsightChronic heart failure (CHF) is a progressive condition where the heart is unable to pump blood effectively leading to significant morbidity and healthcare burden. The growing elderly population inherently at higher risk for CHF is a major driver

Today

$93.24 | +1.88%

Activity

AstraZeneca stock price target raised to $108.50 from $91.70 at BofA.

Today

$93.24 | +1.88%

Potential

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows. Hong Kong-based ) initially established in March 2025.Harbour BioMed is a biopharmaceutical company focused on the discoveryand developmentof antibody therapeutics in .The collaboration to discover and develop next-generation biotherapeutics including antibody-drug conjugates and T cell engagers.Under the terms of the agreement AstraZeneca will continue to nominate discovery programs to Harbour BioMed each ye

Mon Nov 24, 2025

$91.52 | +0.57%

Activity

AstraZeneca expands United States production footprint with $2B investment in Maryland.

Fri Nov 21, 2025

$91.00 | +2.62%

Activity

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug Koselugo. AstraZeneca secures FDA approval to expand Koselugos use to treat adult NF1 patients with inoperable PN.

Fri Nov 21, 2025

$91.00 | +2.62%

Activity

FDA Approval Delivers Momentum For AstraZenecas Rare Disease Portfolio. On Thursday the United States Food and Drug Administration (FDA) approved )Koselugo (selumetinib) for adult patients with neurofibromatosis type 1 (NF1) who have symptomatic inoperable .NF1 is a rare progressive genetic condition caused by a spontaneous or inherited mutation in the NF1 gene.It is associated with a variety of symptoms including soft lumps on and under the skin (cutaneous neurofibromas) and in up to 50% of pat

Thu Nov 20, 2025

$88.78 | -0.35%

Activity

AstraZenecas Alexion gets FDA approval for Koselugo.

Thu Nov 20, 2025

$88.78 | -0.35%

Activity

AstraZeneca: Alexions Koselugo Gets FDA Approval For Adults With Neurofibromatosis Type 1 . (RTTNews) - British drug major AstraZeneca Plc. (AZN.L AZN) announced Thursday that the US Food and Drug Administration has approved Alexion AstraZeneca Rare Diseases Koselugo (selumetinib) for the treatment of adult patients with neurofibromatosis type 1 or NF1 who have sympt

Thu Nov 20, 2025

$88.78 | -0.35%

Activity

AstraZeneca Pharma India shares surge over 3% on new Hyperkalaemia drug deal with Sun Pharma . On Tuesday shares of AstraZeneca Pharma India surged following the announcement of an exciting alliance with Sun Pharmaceutical Industries. Together they are set to enhance the availability of Sodium Zirconium Cyclosilicate which combats hyperkalemia. AstraZeneca will introduce this treatment to the market under the name Lokelma while Sun Pharma will distribute it as Gimliand.

Tue Nov 18, 2025

$89.55 | +0.17%

Activity

Momentum

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AZN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our AZN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

AZN Stock trends

AZN Stock performance

AZN Stock analysis

AZN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN Stock IQ

AZN Target Price

AZN Risk Level

AZN Analysts Opinion

AZN Street Sentiment

AZN Performance Sentiment

Technical Price Levels

Explore our AZN Stock insights

Receive our AZN Daily Alerts

Latest Comments

Latest Comments

AZN Stock IQ

AZN Street Sentiment

AZN Risk Level

Technical Price Levels

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AZN. We're here to help you make informed investment decisions today.

Receive our AZN Daily Alerts

AZN Runner Alarm